Healthcare: On the Agenda - Blood drug could aid heart patients

In a nutshell

Bayer Healthcare has published clinical data supporting the potential benefits of its new blood thinning drug Rivaroxaban. The drug could help hundreds of thousands of heart patients who are at risk of blood clots and strokes from irregular heartbeats. Rivaroxaban could replace warfarin - the drug currently used for blood thinning - after a trial showed it had fewer side effects, simplified dosing and higher tolerance.

Who is affected?

Atrial fibrillation (AF) is the most common cardiac rhythm disorder and affects up to six million people in Europe. In patients with AF, an irregular heartbeat makes them vulnerable to the formation of a blood clot in the atria. One-third of AF sufferers will experience a stroke.

What does it mean?

Bayer Healthcare - which developed the anticoagulant drug alongside Johnson & Johnson pharmaceutical - trialled more than 14,000 patients, comparing once-daily Rivaroxaban to dose-adjusted warfarin. The effectiveness of Rivaroxaban was far superior to warfarin, delivering a 21 per cent risk reduction in strokes. The drug also offers simplified dosing.

PR strategy

Bayer Healthcare charged Athena Medical with handling the UK media outreach for the drug.

Coverage

The drug received extensive coverage globally. In the UK, highlights included a three-minute clip on BBC Breakfast, page 13 of the Daily Mail and page 19 of the Daily Mirror.

21% reduced risk of strokes when using Rivaroxaban compared with warfarin

6m people in Europe affected by atrial fibrillation

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus

Latest Articles

The latest social media fail case study: #myNYPD

The latest social media fail case study: #myNYPD

The NYPD's Twitter fail offers another social media lesson for organisations.

Edelman US chief Mark Hass steps down

Former top lobbyist and H&K CEO Robert Gray passes away at 92

Former top lobbyist and H&K CEO Robert Gray passes away at 92

Robert Gray, an influential Washington, DC, lobbyist and former chairman and CEO of Hill & Knowlton, passed away last Friday. He was 92.

Max Clifford trial jury to reconvene tomorrow after majority verdicts direction

Max Clifford trial jury to reconvene tomorrow after majority verdicts direction

The jury in the trial of celebrity publicist Max Clifford on 11 charges of indecent assault has been sent home for the day after being told by the judge earlier this afternoon that he will now accept majority verdicts.